1. Longo DL. Fauci AS. The Human Retroviruses. In: Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J, Holland S, Langford C, eds. Harrison’s Principles of Internal Medicine, 22nd
Edition. McGraw Hill; 2025.
2. Murray PR. Rosenthal KS. Pfaller MA. Medical Microbiology, 9th Edition. Elsevier;2020.
3. Stubbs EL, Wallbank AM. Avian Virus-Induced Tumors.Poultry Science 1968; 47(%):1448-1452.
4. Rifkind D, Freeman GL. Rous Sarcoma Vırus. In: Rifkind D, Freeman GL,eds. The Nobel Prize Winning Discoveries in Infectious Diseases,Academic Press, 2005: 109-110.
5. https://ictv.global/report/chapter/retroviridae/retroviridae
6. Murphy EL BruhnHuman RL. T-Cell Leukemia Viruses (HTLV-1, HTLV-2). In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas and Bennett’s Principles and Practice of Infectious
Diseses, 9th Edition. Elsevier Saunders: 2020.
7. Murphy EL, Bruhn RL: Human T-cell Leukemia Viruses Types 1 and 2, In: Murphy EL, Bruhn RL, Kaslow RA et al(eds.) Viral Infections of Humans, Springer Science and Business Media
New York, 2014: 1105
8. Swıtzer WM, Heneıne W, Owen SM. Human T-Cell Lymphotropic Viruses. In: Carroll KC, Pfaller MA, Karlowsky JA, Landry MA, Mcadam AJ, Patel R, Pritt BS,eds. Manual of Clinical
Microbiology, 13th Edition. ASM, 2023.
9. Yenen O Ş. Kan Donörlerinde ve çeşitli hasta gruplarında anti-HTLV-I seroprevalansı. Türk Mikrobiyol Cem Derg 1988; 18: 47.
10. Yenen O Ş, Beyazyürek M, Keskin K, ve ark. Damariçi uyuşturucu bağımlılarında HbsAg, Anti-HBc, Anti-HCV, anti-HTLV-1, anti-HIV-1/2 araştırması. KLİMİK Derg 1993; 1:35.
11. Sertöz R, Erensoy S, Özçam H, Altuğlu İ, Taşbakan M, Töbü M, Bilgiç A: Anti-HTLV-I/II Seroprevalence in Healthy Blood Donors in İzmir, TurkeyTurk J Haematol 2003;20(2):81-83.
12. Sertöz R, Turhan A, Bozkurt H, Samlıoğlu P, Değirmenci A, Aydınok Y, Erensoy S: Investigation of anti-HTLV I/II seroprevalence in healthy blood donors in Izmir region, Turkey, Mikrobiyol
Bul. 2010 Oct;44(4):579-84.
13. Goff S P: Retroviridae In: Knipe DM, Howley PM, Cohen JI, Griffin DE, Lamb RA, Martin MA, Racaniello VR, Roizman B(eds) Field’s Virology Wolter Kluwer, Lipponcott Williams and
Wilkins, USA, 2013:1424.14.
14. Krutzkes D R, Walker B D: HIV-1: pathogenesis, clinical manifestations and treatment In: Knipe D M, Howley P M (eds) Fiedls Virology fifth ed. Wolters KluwerUSA 2007:2187.
15. Fauci AS. Folkers GK. Lane H. Human Immunodeficiency Virus Disease: AIDS and Related Disorders. In: Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J, Holland S, Langford
C, eds. Harrison’s Principles of Internal Medicine, 22nd Edition. McGraw Hill; 2025.
16. Johnson J, Mascıotra S, Owen SM.Human Immunodeficiency Viruses. In: Carroll KC, Pfaller MA, Karlowsky JA, Landry MA, Mcadam AJ, Patel R, Pritt BS,eds. Manual of Clinical Microbi-
ology, 13th Edition. ASM, 2023.
17. Dimmock NJ, Easton AJ, Leppard KN, Introduction to Modern Virology, 7th Edition Wiley-Blackwell 2016.
18. Sharp PM, Hahn BH. Origins of HIV and AIDS pandemic. Coldspring Harb. Perspect. Med 2011. 1:a006841 .
19. Maartens G, Cellum C, Revin SR, HIV infection: Epidemiology Pathogenesis Treatment and prevention. Lancet 2014; 384:258-271.
20. Ibe S, Yokomaku Y, Shiino T, Tanaka R, Hattori J, Fujisaki S, Iwatani Y, Mamiya N, Utsumi M, Kato S, Hamaguchi M, Sugiura W. HIV-2 CRF01_AB: first circulating recombinant form of
HIV-2. J Acquir Immune Defic Syndr. 2010 Jul;54(3):241-7.
21. Yalçinkaya T, Köse S. HIV-1 Subtiplerinin Dağılımı. Türk Mikrobiyol Cem Derg 2011 41(3):116-119, doi:10.5222/TMCD.2011.116
22. Kuşkucu MA, Midilli K, Mete B, Aydın ÖA, Yemişen M, Karaosmanoğlu HK, Ergin S, Tabak F. İstanbul’da Naif HIV ile İnfekte Kişilerde 10 Yıllık Döneme Ait Nakledilmiş Direnç Oranları ve
Genotip Dağılımları. 3. Ulusal Klinik Mikrobiyoloji Kongresi Belek, Antalya, 2015.
23. Yılmaz G, Midilli K, Türkoğlu K, Bayraktaroğlu Z, Kuşkucu M, Özkan E, Atasever L, Çalangu S, Atlaş K. Genetic subtypes of human immunodeficiency virus type 1 (HIV-1) in İstanbul,
Turkey International Journal of Infectious Diseases (2006) 10, 286.
24. Yılmaz G, Midilli K, İstanbullu A, Türkoğlu A, Çalangu S, Altaş K: Türkiyede ilk kez saptanan rekombinant HIV-1 ile infekte 2 olgu s.101,2. Ulusal AIDS Sempozyumu s.100, 2004.
25. Sayan M, Willke A, Özgüneş N, Sargın F: HIV-1 subtypes and primary antiretroviral resistance mutations in antiretroviral therapy naive HIV-1 infected individuals in Turkey, Jpn J Infect Dis.
2013;66(4):306).
26. Yılmaz G, Akalın H, Işık N, Assaf A H, Töre O, Badur S. First documented case of human ımmunodeficiency virus type 2 infection in Turkey. Serodiag and Immunother in Infect Dis 1996;
8:125
27. www.unaids.org/sites/default/files/mediz_asset/UNAIDS_FactSheet_en.pdf
28. Global summary of the AIDS epidemic 2014. http://www.who.int/hiv/data/epi_core_july2015.
29. Joint United Nations Programme on HIV/ AIDS. The Gap Report. September 2014 http:// www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf (Accessed on May
20, 2015).
30. Global update on the health sector response to HIV, 2014. WHO, July 2014. http://www.who. int/hiv/pub/progressreports/update2014/en/
31. https://www.unaids.org/sites/default/files/2025-07/2025_Global_HIV_Factsheet_en.pdf
32. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü Bulaşıcı Hastalıklar ve Erken Uyarı Dairesi Başkanlığı, HIV/AIDS İstatistikleri https://hsgm.saglik.gov.tr/depo/birimler/bulasici-hastalik-
lar-ve-erken-uyari-db/Dokumanlar/Istatistikler/HIV_AIDS_Istatistikleri.pdf
33. Gokengin D, Cimen, C., Cagatay, A, et al. HIV cascade of care in Turkey: data from the HIV-TR cohort. HIV Medicine 2019; 20:112-113.
34. Erdinç FS, Dokuzoğuz B, Ünal S, et al. Changing trends in the epidemiology of Turkey. 30th IUSTI Europe Conference Budapest, Hungary, 2016.
35. Moir S, Connors M, Fauci AS. The immunology of human immunodeficiency virus infection. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas and Bennett’s Principles and Practice
of Infectious Diseses, 9th Edition. Elsevier Saunders: 2020.
36. CDC, Revised Surveillance Case Definition for HIV Infection-United States, 2014. MMWR Recomm Rep 2014; 63:1.
37. Gottlieb GS, Epidemiology transmition Natural history of HIV-2 infection. www.uptodate.com/contets/epidemiology-transmition-natural-history-and-pathogenesis-hıv-2-infection.
38. https://www.cdc.gov/hivnexus/hcp/diagnosis-testing/index.html.
39. Brian R Wood, MD The natural history and clinical features of HIV infection in adults and adolescents, Feb 15, 2023., Uptodate.
40. CDC: Suggested Reporting Language for the HIV Laboratory Diagnostic Testing Algorithm https://stacks. cdc.gov/view/cdc/76017, Ocak 2019
41. https://www.emro.who.int/asd/about/testing-counselling.html
42. https://www.cdc.gov/hiv/guidelines/recommendations/technical-update-for-hiv.html: Technical Update for HIV Nucleic Acid Tests Approved for Diagnostic Purposes
43. Management of Infants Born to People with HIV Infection, https://clinicalinfo.hiv.gov/en/guidelines/perinatal/management-infants-diagnosis-hiv-infection-children 31 Ocak2023
44. Paul E Sax, MDAcute and early HIV infection: Clinical manifestations and diagnosis: Jan 2024, Uptodate
45. T.C. Sağlik Bakanliği Halk Sağliği Genel Müdürlüğü HIV/AIDS Tani Klavuzu Ankara 2018, https://hsgm.saglik.gov.tr/tr/mikrobiyoloji-rehberler.html veya https://dosyahastane.saglik.gov.tr/
Eklenti/37603,hiv-aids-tani-klavuzupdf.pdf
46. T.C. Sağlık Bakanlığı HIV/AIDS Tedavi Rehberi 2019
47. Can R, Çelik G: Hıv/Aıds Göz Ardı Etmeyelim, https://www.klimud.org/uploads/content/Hiv_Aids%20Elkitab%C4%B1%20Haziran2024.pdf.
48. http://thsk.saglik.gov.tr/eDosya/bulasici-hastaliklar-db/hiv_aids_tani_tedavi_rehberi_2013.pdf
49. KLİMİK: HIV/AIDS Tanı İzlem Tedavi El kitabı, klimik.org.tr/2024/02/12/hiv-aids-tani-izlem-ve-tedavi-el-kitabi.
50. Centers for Disease Control and Prevention (CDC). 2008. https://www.cdc.gov/infection-control/media/pdfs/guideline-disinfection-h.pdf
Antiretroviral Direnç ve Tayini
KAYNAKLAR
1. Shafer RW. Genotypic Testing for HIV-1 Drug Resistance. In: Peiperl L, Coffey S, Volberding PA, eds. HIV InSite Knowledge Base [textbook online]; San Francisco: UCSF Center for HIV
Information; April 2004. Accessed April, 2006. Available online at hivinsite.ucsf.edu/InSite?page=KB.
2. Shafer RW and Schapiro. Drug resistance and antiretroviral drug development. J Antimicrob Chemother 2005, 55:817.
3. Markowitz M, Louie M, Hurley A et al. A novel antiviral intervention results in more accurate assessment of HIV type 1 replication dynamics and T-cell decay in vivo. J Virol 2003, 77:5037.
4. Haché G, Mansky LM and Harris RS. Human APOBEC3 proteins, retrovirus restriction and HIV drug resistance. AIDS Rev 2006, 8: 148-57
5. Bennett DE, Camacho RJ, Otelea D ve ark. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009;4(3):e4724.
6. Dunna DT, Coughlina K and Cane PA. Genotypic resistance testing in routine clinical care. Current Opinion in HIV and AIDS 2011, 6:251–257.
7. Herbert S, Chung E, Waters L. HIV Treatment. Current Treatment Options in Infectious Diseases, 2014,
8. Wensing AM, Calvez V, Günthard HF, Johnson VA, Paredes R, Pillay D, et all. 2015 Update of the Drug Resistance Mutations in HIV-1 Topics in Antiviral Medicine 2015 23(4), 132-141
9. Gupta RK and Pillay B. HIV resistance and the developing world. Int J Antimicrob Agents 2007, May;29(5):510-7.
10. Gallant JE, Edit; Hirsch MS, Mitty J. Primer on interpretation of HIV drug resistance testing. UpToDate 2016, http://www.uptodate.com/contents/primer-on-interpretation-of-hiv-drug-re-
sistance-testing?source=search_result&search=primer+on+interpretation+of+hiv+drug+resistance+testi&selectedTitle=3%7E150.
11. Simen BB, Simons JF, Hullsiek KH, et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment
outcomes. J Infect Dis 2009; 199:693.
12. Chabria SB, Gupta S, Kozal MJ. Deep sequencing of HIV: clinical and research applications. Annu Rev Genomics Hum Genet 2014; 15:295.
13. Shafer RW. Low-abundance drug-resistant HIV-1 variants: finding significance in an era of abundant diagnostic and therapeutic options. J Infect Dis 2009; 199:610.
14. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/sites/default/files/
guidelines/archive/AdultandAdolescentGL_2021_08_16.pdf
15. https://hivinfo.nih.gov/understanding-hiv/fact-sheets/fda-approved-hiv-medicines
16. Zhou N, Nowicka-Sans B, Zhang S, et al. In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043. Antimicrob Agents Chemother. 2011 Feb;55(2):729-37.
17. Bester SM, Adu-Ampratwum D, Annamalai AS, et al. Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir. mBio. 2022 Oct 26;13(5):e0180422.
18. Gatanaga H, Murakoshi H, Hachiya A, et all. Naturally Selected Rilpivirine-Resistant HIV-1 Variants by Host Cellular Immunity. Clinical Infectious Diseases 2013;57(7):1051–5
19. Lübke N, Di Cristanziano V, Sierra S, et all. Proviral DNA as a Target for HIV-1 Resistance Analysis. Intervirology 2015; 58:184–189.
20. Derache A, Shin HS, Balamane M, et al. HIV Drug Resistance Mutations in Proviral DNA from a Community Treatment Program. PLoS ONE, 2015, 10(1):e0117430.
21. Cihlar T and Fordycem M. Current status and prospects of HIV treatment. Curr. Cur Open Virol. 2016, 18:50-56.
22. Ng BE, Butller LM, Horvat T, Ratherford GW. Population based biomedical sexually transmited infection control interventions for reducing HIV infection. Cochrane Database, Syst Rev.
2011 (3): CD001220